RxDoctor Payments Data

Thapasya Rein, APRN

Acute Care · Columbus, OHNPI 1942816400

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 26 payments — averaging $41.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$351
  • Antares Pharma, Inc.$247
  • Boston Scientific$183
  • Sumitomo Pharma America, Inc.$143
  • Convatec Inc.$64
  • Teleflex LLC$33
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$96791%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 75th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$23,625
Medicare patients
159
Services billed
3,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron94$78,632
Tamsulosin Hcl503$7,200
Solifenacin Succinate59$3,319
Methenamine Hippurate24$3,311
Desmopressin Acetate30$2,818
Tolterodine Tartrate ErTolterodine Tartrate20$2,438
Finasteride189$2,160
Trospium Chloride24$1,682
Oxybutynin Chloride ErOxybutynin Chloride79$1,644
Testosterone Cypionate17$782
Estradiol13$720
Potassium Citrate ErPotassium Citrate11$713
Testosterone11$511
Doxazosin Mesylate29$477
Alfuzosin Hcl ErAlfuzosin Hcl24$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$351$78,63294 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,101 acute care providers in Ohio.

Other acute care in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →